Delving into the Latest Updates on Gemeprost with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

16,16-Dimethyl-trans-delta(sup 2)-prostaglandin E1 methyl ester, 16,16-Dimethyl-trans-delta-2-PGE1 methyl ester, Gemeprost (JAN/USAN/INN)

+ [6]

Target

EP1

Action

agonists

Mechanism

EP1 agonists(Prostanoid EP1 receptor agonists)

Therapeutic Areas

Other Diseases

Active Indication

Induced Abortion

Inactive Indication-

Originator Organization

Ono Pharmaceutical Co., Ltd.

Active Organization

Ono Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (30 May 1984),

Induced Abortion

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H38O5

InChIKeyKYBOHGVERHWSSV-VNIVIJDLSA-N

CAS Registry64318-79-2

The Clinical trial aim to evaluate the effectiveness and safety of the administration of the intravenous prostaglandin E1 analog in the reduction of mortality and complications of patients with COVID-19 diagnosis. Therefore the investigators propose an open randomized clinical trial in the Fundación Santa Fe de Bogota

Start Date03 Dec 2020

Sponsor / Collaborator-

100 Clinical Results associated with Gemeprost

Login to view more data

100 Translational Medicine associated with Gemeprost

Login to view more data

100 Patents (Medical) associated with Gemeprost

Login to view more data

363

Literatures (Medical) associated with Gemeprost

01 Jan 2024·Journal of Gynecology Obstetrics and Human Reproduction

Abortion medical management between 14−16 weeks’ amenorrhea after French legislation deadline extension

Article

Author: Gauci, Pierre-Alexis ; Delotte, Jérôme ; Carpentier, Hortense

BACKGROUNDThe National French Assembly promoted a law in 2022 allowing an extension of the period of abortion up to 16 week's amenorrhea. Medication protocols vary internationally, and there are no French data on medical management between 14- and 16-weeks' amenorrhea.OBJECTIVETo assess effectiveness and feasibility of a medical management abortion between 14 and 16 weeks of amenorrhea.STUDY DESIGNWe retrospectively collected data from women undergoing medical abortion between 14 and 16 weeks' amenorrhea from April 2022 to April 2023 in Archet's University hospital, Nice, France. Medical protocol consisted in a single dose of oral mifepristone 600 mg and 36-48 h later, vaginal gemeprost 1 mg. Three hours after gemeprost, oral 400 µg of misoprostol were administered every three hours, to a maximum of three doses. Success was defined as fetal expulsion.RESULTSThirty women were enrolled in the study. Twenty-nine (96.7 %) patients aborted successfully. The median dose of misoprostol required was 800 µg (400 µg -1200 µg) and the median induction-to-abortion interval after first prostaglandin administration was 7 h (5.5-11.6). One patient (3.3 %) didn't expulse the fetus after 3 doses of misoprostol. Nine patients (30.0 %) had additional surgical aspiration for retained product of conception within 24 h. We encountered one post-abortum hemorrhage controlled only with surgical intra uterine aspiration. We did not need complementary hemostatic procedure and we reported no immediate or late complication.CONCLUSIONSMedical abortion between 14 and 16 weeks of amenorrhea provides a noninvasive and effective management for a daycare mid trimester abortion in 96.7 % of cases, with a 36.7 % of risk of staying in hospital overnight and 30.0 % to have additional surgery for retained product of conception (RPOC).

03 Oct 2023·Cureus

Exploring the Safety and Efficacy of Medical Termination of Pregnancy: A Comprehensive Review

Review

Author: Bawiskar, Dushyant ; Leichombam, Rajshree

Medical termination of pregnancy, also known as medication abortion, is a safe and effective method of terminating pregnancies in the early stages. It involves using medications, such as mifepristone and prostaglandin, to induce a miscarriage. The success rates of medical abortion vary depending on factors such as gestational age and the specific medications used. For pregnancies that are 49 days or less, the success rates range from 92% to 98%. The choice between misoprostol and gemeprost, both prostaglandins, does not significantly impact the outcomes. It is important to note that various factors, including study design, definitions of success, and prior experience with medical abortion may influence success rates. Strict criteria for success and limited familiarity with the procedure may result in lower reported success rates. Medical termination of pregnancy should be carried out under the guidance and supervision of healthcare professionals. It is crucial to consult a healthcare provider to receive accurate information, personalized guidance, and appropriate support throughout the process. Each situation is unique, and decisions regarding medical termination of pregnancy should be made in collaboration with a trusted healthcare provider.

03 Apr 2022·Journal of Obstetrics and GynaecologyQ4 · MEDICINE

Risk factors of retained products of conception after miscarriage or termination with gemeprost in the second trimester of pregnancy: a retrospective case-controlled study in Japanese population

Q4 · MEDICINE

Article

Author: Noguchi, Tomoko ; Mizoguchi, Mika ; Nanjo, Sakiko ; Minami, Sawako ; Ota, Nami ; Yagi, Shigetaka ; Mabuchi, Yasushi ; Shiro, Michihisa ; Ino, Kazuhiko

Retained products of conception (RPOC) is a complication that occurs in the second trimester of pregnancy. We enrolled 98 women who had a miscarriage or termination with gemeprost in the second trimester of pregnancy. Eighteen cases (18.4%) were RPOC-positive. The gestational week at miscarriage or termination was earlier in the RPOC-positive group than those in the RPOC-negative group (p = .003). The period of the third stage of labour was longer in the RPOC-positive group than in RPOC-negative group (p = .040). The proportion of placental forceps use was higher in the RPOC-positive group than in RPOC-negative group (p = .003). Multivariate logistic regression analysis showed that gestational week (OR: 3.53; p = .04) and use of placental forceps at delivery (OR: 2.21; p = .012) were independent risk factors for RPOC. Earlier gestational weeks at miscarriage or termination and use of placental forceps at delivery were predictive factors for RPOC after second trimester miscarriage or termination with gemeprost.Impact StatementWhat is already known on this subject? There have been some reports on risk factors of RPOC. A previous report showed that the termination of pregnancy with misoprostol at earlier periods was associated with an increased risk of RPOC.What the results of this study add? There have been few studies on the risk factors of RPOC after miscarriage or termination with gemeprost. In this study, we evaluated the risk factors of RPOC after miscarriage or termination of pregnancy with gemeprost in the second trimester. We found that an earlier gestational age (between 12 and 17 weeks) at delivery and using placental forceps to remove placenta were significant risk factors of RPOC after miscarriage or termination of pregnancy with gemeprost in the second trimester.What the implications are of these findings for clinical practice and/or further research? An earlier gestational age and using forceps to remove placenta may be significant risk factors for RPOC. The accurate evaluation and treatment for RPOC is important for maternal life-saving efforts and subsequent pregnancies. Further research is needed to draft a standardised protocol for RPOC.

100 Deals associated with Gemeprost

Login to view more data